Abstract
Abstract Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis. While adverse skin reactions occur in 90% of patients treated with angiogenesis inhibitors, only a few cases of psoriasiform eruption associated with sorafenib therapy have been reported. We report a rare case of sorafenib-related psoriasis that responded well to topical treatment and narrow-band UV-B phototherapy after discontinuation of sorafenib.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
